Development of a universal CTL-based vaccine for influenza
Development of a universal CTL-based vaccine for influenza
复制标题
DOI：
10.4161/bioe.23573
复制
发表时间：
2013-11-01
期刊：
影响因子：
4.9
通讯作者：
Alberto Scodeller, Eduardo
中科院分区：
文献类型：
--
作者：
Esteban Cargnelutti, Diego;Victoria Sanchez, Maria;Alberto Scodeller, Eduardo
为了追求更好的流感疫苗，世界各地都在研究许多策略。一个有吸引力的替代方案是基于诱导针对甲型流感病毒保守内部抗原的细胞毒性T淋巴细胞(CTL)而产生一种广泛交叉反应的疫苗。最近，几个研究小组在小鼠和人类身上证明了使用重组病毒载体的这种方法的可行性。然而，用原核系统中表达的病毒蛋白进行免疫也可能达到类似的结果，该系统由适当的佐剂和输送系统配制而成。这种方法会简单得多，成本也更低。最近几个实验室的结果似乎证实了这是一个值得考虑的有效选择。
In pursuit of better influenza vaccines, many strategies are being studied worldwide. An attractive alternative is the generation of a broadly cross-reactive vaccine based on the induction of cytotoxic T-lymphocytes (CTL) directed against conserved internal antigens of influenza A virus. The feasibility of this approach using recombinant viral vectors has recently been demonstrated in mice and humans by several research groups. However, similar results might also be achieved through immunization with viral proteins expressed in a prokaryotic system formulated with the appropriate adjuvants and delivery systems. This approach would be much simpler and less expensive. Recent results from several laboratories seem to confirm this is as a valid option to be considered.